Early effects of treatment low-dose atorvastatin on markers of insulin resistance and inflammation in patients with myocardial infarction

Frontiers in Pharmacology

Volumn 7, Issue SEP, 2016, Pages

  Gruzdeva, Olga ^a   Uchasova, Evgenya ^a   Dyleva, Yulia ^a   Akbasheva, Olga ^b   Karetnikova, Victoria ^a   Barbarash, Olga ^a  

^a RESEARCH INSTITUTE FOR COMPLEX ISSUES OF CARDIOVASCULAR DISEASES   (Russian Federation)

^b SIBERIAN STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Adipokine; Inflammation; Lipid; Myocardial infarction; Statin

Indexed keywords

APOLIPOPROTEIN A; ATORVASTATIN; C REACTIVE PROTEIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LEPTIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FATTY ACID BLOOD LEVEL; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LENGTH OF STAY; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84991824182     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00324     Document Type: Article

References (18)

1. Alessi, M., and Juhan-Vague, I. (2006). PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler. Thromb. Vasc. Biol. 26, 2200-2207. doi: 10.1161/01.ATV.0000242905.41404.68
2. Aronov, D. M. (2004). Statins: therapeutic cascade of their effects. Kardiologiia 44, 85-94. (Russian).
3. Bakker-Arkema, R. G., Davidson, M. H., Goldstein, R. J., Davignon, J., Isaacsohn, J. L., Weiss, S. R., et al. (1996). Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275, 128-133. doi: 10.1001/jama.1996.03530260042029
4. Cefalu, W. T. (2001). Insulin resistance: cellular and clinical concepts. Exp. Biol. Med. 226, 13-26.
5. Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., et al. (1999). Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253-259. doi: 10.1172/JCI5001
6. Gotto, A. M. Jr., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., et al. (2000). Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101, 477-484. doi: 10.1161/01.CIR.101.5.477
7. Gupta, A., Badyal, D. K., Khosla, P. P., Uppal, B., Jaison, T. M., and Chopra, S. (2008). Effect of atorvastatin on hs-CRP in acute coronary syndrome. Br. J. Clin. Pharmacol. 66, 411-413. doi: 10.1111/j.1365-2125.2008.03172.x
8. Hui, X., Feng, T., Liu, Q., Gao, Y., and Xu, A. (2016). The FGF21-adiponectin axis in controlling energy and vascular homeostasis. J. Mol. Cell Biol. 8, 110-119. doi: 10.1093/jmcb/mjw013
9. Ichihara, K., and Satoh, K. (2002). Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 359, 2195-2198. doi: 10.1016/S0140-6736(02)09098-0
10. Killip, T., and Kimball, J. T. (1967). Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am. J. Cardiol. 20, 457-464. doi: 10.1016/0002-9149(67)90023-9
11. Kryzhanovsky, V. A. (2001). Diagnosis and Treatment of Myocardial Infarction. Phoenix, AZ.
12. Li, S., Shin, H. J., Ding, E. L., and van Dam, R. M. (2009). Adiponectin levels and risk of type 2 diabetes: a systematic reviewand meta-analysis. JAMA 302, 179-188. doi: 10.1001/jama.2009.976
13. Martin, S. S., Qasim, A., and Reilly, M. P. (2008). Leptin Resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J. Am. Coll. Cardiol. 52, 1201-1210. doi: 10.1016/j.jacc.2008.05.060
14. Pedersen, T. R., Kjekshus, J., Berg, K., Haghfelt, T., Faergeman, O., Faergeman, G., et al. (2004). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler. Suppl. 5, 81-87. doi: 10.1016/j.atherosclerosissup.2004.08.027
15. Rodríguez-Calvo, R., Barroso, E., Serrano, L., Coll, T., Sánchez, R. M., Merlos, M., et al. (2009). Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activatin protein kinase. Hepatology 49, 106-115. doi: 10.1002/hep.22570
16. Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., et al. (2008). Heart diseases and stroke statistics-2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, 25-146. doi: 10.1161/CIRCULATIONAHA.107.187998
17. Thygesen, K., Alpert, J. S., and White, H. D. (2007). Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. Circulation 116, 2634-2653. doi: 10.1161/CIRCULATIONAHA.107.187397
18. Wallander, M., Söderberg, S., and Norhammar, A. (2008). Leptin: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known Type 2 diabetes. Diabet. Med. 25, 949-955. doi: 10.1111/j.1464-5491.2008.02509.x